Total Payments
$499,442
2024 Payments
$117,992
Companies
17
Transactions
319
Medicare Patients
3,403
Medicare Billing
$437,959
Payment Breakdown by Category
Other$242,355 (48.5%)
Consulting$160,855 (32.2%)
Research$49,887 (10.0%)
Travel$38,205 (7.6%)
Food & Beverage$8,141 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $237,980 | 64 | 47.6% |
| Consulting Fee | $160,855 | 35 | 32.2% |
| Unspecified | $49,887 | 18 | 10.0% |
| Travel and Lodging | $38,205 | 99 | 7.6% |
| Food and Beverage | $8,141 | 102 | 1.6% |
| Honoraria | $4,375 | 1 | 0.9% |
Payments by Type
General
$449,555
301 transactions
Research
$49,887
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PROGENICS PHARMACEUTICALS, INC. | $224,389 | 164 | $0 (2024) |
| Blue Earth Diagnostics Limited | $126,319 | 27 | $0 (2024) |
| Lilly USA, LLC | $55,041 | 33 | $0 (2017) |
| Advanced Accelerator Applications | $39,368 | 46 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $30,637 | 16 | $0 (2023) |
| GE HEALTHCARE | $7,524 | 15 | $0 (2024) |
| Eisai Inc. | $6,517 | 2 | $0 (2023) |
| Avid Radiopharmaceuticals, Inc. | $4,594 | 4 | $0 (2024) |
| Eli Lilly and Company | $1,725 | 1 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,595 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $117,992 | 88 | PROGENICS PHARMACEUTICALS, INC. ($108,297) |
| 2023 | $85,407 | 66 | Progenics Pharmaceuticals, Inc. ($64,348) |
| 2022 | $37,586 | 39 | Progenics Pharmaceuticals, Inc. ($30,020) |
| 2021 | $112,298 | 18 | Blue Earth Diagnostics Limited ($110,985) |
| 2020 | $15,242 | 28 | Advanced Accelerator Applications ($4,825) |
| 2019 | $65,034 | 35 | Advanced Accelerator Applications ($30,009) |
| 2018 | $6,168 | 6 | Advanced Accelerator Applications ($4,481) |
| 2017 | $59,715 | 39 | Lilly USA, LLC ($55,041) |
All Payment Transactions
319 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 11/26/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| 11/18/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,560.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 11/18/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $418.08 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 11/18/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $123.97 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/17/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,560.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/17/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $161.18 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/17/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $117.85 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/17/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $115.61 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/16/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,560.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/16/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $1,711.22 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/16/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $317.29 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/16/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $141.56 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/16/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $123.43 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/16/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $32.38 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/15/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,360.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/15/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $100.80 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/15/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $23.72 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 10/09/2024 | GE HEALTHCARE | Vizamyl (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: Pharma Imaging Agents - Nuclear Imaging | ||||||
| 10/09/2024 | GE HEALTHCARE | Vizamyl (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Pharma Imaging Agents - Nuclear Imaging | ||||||
| 10/04/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $1,217.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 09/11/2024 | GE HEALTHCARE | — | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| 09/04/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,720.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 09/04/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $615.44 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 09/04/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $148.31 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | Regeneron Pharmaceuticals, Inc. | $19,513 | 14 |
| IB12B PMR ICON | Progenics Pharmaceuticals, Inc. | $19,250 | 2 |
| Outcomes in Patients With Relapse/Refractory Diffuse Large B-Cell Lymphoma Treated With Systemic Therapy From Real-World Experience (ORCHID) | Regeneron Pharmaceuticals, Inc. | $11,125 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 900 | 1,110 | $1.0M | $266,425 |
| 2022 | 18 | 827 | 875 | $211,836 | $55,880 |
| 2021 | 15 | 863 | 909 | $222,334 | $60,865 |
| 2020 | 14 | 813 | 864 | $198,919 | $54,789 |
Total Patients
3,403
Total Services
3,758
Medicare Billing
$437,959
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2023 | 21 | 181 | $184,982 | $88,569 | 47.9% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 61 | 61 | $452,132 | $72,912 | 16.1% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 73 | 73 | $38,690 | $30,200 | 78.1% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2023 | 250 | 265 | $99,216 | $24,736 | 24.9% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 20 | 20 | $173,118 | $23,921 | 13.8% |
| 78582 | Nuclear medicine study of lung ventilation and circulation | Facility | 2023 | 119 | 119 | $19,516 | $5,067 | 26.0% |
| 78830 | Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | Facility | 2023 | 82 | 83 | $20,086 | $4,735 | 23.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 61 | 61 | $14,884 | $3,975 | 26.7% |
| 78816 | Nuclear medicine study whole body with ct scan | Facility | 2023 | 29 | 32 | $12,076 | $3,131 | 25.9% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Facility | 2023 | 77 | 86 | $11,352 | $2,881 | 25.4% |
| 79101 | Radioactive drug therapy through a vein | Facility | 2023 | 14 | 22 | $6,651 | $1,738 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 13 | 26 | $3,354 | $1,432 | 42.7% |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | Facility | 2023 | 33 | 33 | $5,313 | $1,425 | 26.8% |
| 78227 | Nuclear medicine study of liver and bile duct system with use of drugs | Facility | 2023 | 35 | 36 | $5,004 | $1,316 | 26.3% |
| 78264 | Nuclear medicine study of stomach to assess emptying | Facility | 2023 | 12 | 12 | $1,368 | $386.16 | 28.2% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2022 | 222 | 242 | $90,607 | $23,835 | 26.3% |
| 78582 | Nuclear medicine study of lung ventilation and circulation | Facility | 2022 | 132 | 132 | $21,648 | $5,737 | 26.5% |
| 78830 | Nuclear medicine study, 1 area with spect and concurrent ct scan | Facility | 2022 | 87 | 87 | $22,645 | $5,110 | 22.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 64 | 64 | $15,616 | $4,353 | 27.9% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Facility | 2022 | 89 | 101 | $13,332 | $3,495 | 26.2% |
| 78816 | Nuclear medicine study whole body with ct scan | Facility | 2022 | 24 | 24 | $9,024 | $2,337 | 25.9% |
| 79101 | Radioactive drug therapy through a vein | Facility | 2022 | 18 | 23 | $6,785 | $1,917 | 28.3% |
| 78832 | Nuclear medicine study, multiple areas with spect and concurrent ct scan | Facility | 2022 | 18 | 18 | $6,192 | $1,554 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 16 | 24 | $3,096 | $1,364 | 44.1% |
| 78803 | Nuclear medicine study, 1 area with spect | Facility | 2022 | 30 | 30 | $4,830 | $1,328 | 27.5% |
About Dr. Giuseppe Esposito, MD
Dr. Giuseppe Esposito, MD is a Nuclear Imaging & Therapy healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1114918141.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Giuseppe Esposito, MD has received a total of $499,442 in payments from pharmaceutical and medical device companies, with $117,992 received in 2024. These payments were reported across 319 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($237,980).
As a Medicare-enrolled provider, Esposito has provided services to 3,403 Medicare beneficiaries, totaling 3,758 services with total Medicare billing of $437,959. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Nuclear Imaging & Therapy
- Other Specialties Nuclear Medicine
- Location Washington, DC
- Active Since 10/31/2005
- Last Updated 04/23/2024
- Taxonomy Code 207UN0902X
- Entity Type Individual
- NPI Number 1114918141
Products in Payments
- PYLARIFY (Drug) $202,664
- AMYVID (Drug) $53,327
- LUTATHERA (Drug) $29,837
- Axumin (Drug) $8,784
- Vizamyl (Drug) $5,000
- LUTATHERA (lutetium Lu 177 dotatate) (Drug) $4,481
- POSLUMA (Drug) $1,950
- Aliqopa (Drug) $1,595
- ILLUCCIX (Drug) $892.65
- DISEASE STATE (Drug) $106.86
- NETSPOT (kit for the preparation of gallium Ga 68 dotatate for injection) (Drug) $53.52
- NEURACEQ (Drug) $24.69
- TheraSphere Y90 Glass Microspheres 10 GBq (Device) $20.21
- VYNDAQEL (Drug) $19.64
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.